# Gilead Sciences, Inc.  Share Price Target ‘$86.21’, now 18.1% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc.share-price-target-86.21-now-18.1-upside-potential/4121145308
- Published: 2024-02-29T13:39:38+00:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** which can be found using ticker (GILD) now have 24 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between $120.00 and $69.00 calculating the average 
target share price we see $86.21. (at the time of writing). Given that the stocks
previous close was at $73.02 this is indicating there is a potential upside of 18.1%.
The 50 day MA is $78.94 and the 200 moving average now moves to $77.68. The market
cap for the company is 90.57B. The current share price for the company is: $72.70
USD

 The potential market cap would be $106,927,171,145 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 16.16, revenue per share of $21.73
and a 9.31% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on: